- Thinly traded nano cap BiondVax Pharmaceuticals (NASDAQ:BVXV) is up 9% premarket on increased volume in response to its announcement of positive results from a Phase 2b clinical trial assessing universal flu vaccine candidate M-001. The study met both endpoints of safety and influenza-specific cellular immune responses.
- The company intends to advance M-001 into Phase 3 development.
BiondVax universal flu vaccine candidate successful in mid-stage study; shares ahead 9% premarket
Recommended For You
More Trending News
About SCNI Stock
Related Stocks
Symbol | Last Price | % Chg |
---|---|---|
SCNI | - | - |
Scinai Immunotherapeutics Ltd. |